A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 [telcagepant] With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura
Latest Information Update: 09 May 2022
Price :
$35 *
At a glance
- Drugs Telcagepant (Primary) ; Zolmitriptan
- Indications Migraine
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 09 Jun 2019 Trial has been completed in Netherlands.
- 27 Jun 2008 Results presented at American Headache Society annual meeting 2008.
- 23 Oct 2007 Status changed from in progress to completed.